MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 593079 | Name: Avanafil dibesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Avanafil dibesylate is a PDE5 inhibitor.

Chemical Structure

Avanafil dibesylate
Avanafil dibesylate
CAS#330784-48-0 (dibesylate)

Theoretical Analysis

MedKoo Cat#: 593079

Name: Avanafil dibesylate

CAS#: 330784-48-0 (dibesylate)

Chemical Formula: C35H38ClN7O9S2

Exact Mass: 799.1861

Molecular Weight: 800.30

Elemental Analysis: C, 52.53; H, 4.79; Cl, 4.43; N, 12.25; O, 17.99; S, 8.01

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
330784-47-9 (free base) 330784-48-0 (dibesylate) Avanafil metabolite M4 2748151-94-0 (metabolite M16)
Synonym
Avanafil dibesylate; Avanafil dibesilate; Avanafil dibenzenesulfonate; TA1790 dibenzenesulfonate; TA 1790 dibenzenesulfonate; TA-1790 dibenzenesulfonate
IUPAC/Chemical Name
(S)-4-((3-chloro-4-methoxybenzyl)amino)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide dibenzenesulfonate
InChi Key
DTNQLMYRSLBWLF-SQKCAUCHSA-N
InChi Code
InChI=1S/C23H26ClN7O3.2C6H6O3S/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32;2*7-10(8,9)6-4-2-1-3-5-6/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30);2*1-5H,(H,7,8,9)/t16-;;/m0../s1
SMILES Code
COC1=C(Cl)C=C(CNC2=NC(N3CCC[C@H]3CO)=NC=C2C(NCC4=NC=CC=N4)=O)C=C1.O=S(C5=CC=CC=C5)(O)=O.O=S(C6=CC=CC=C6)(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 800.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Can NÖ. Development of Validated and Stability-Indicating LC-DAD and LC-MS/MS Methods for Determination of Avanafil in Pharmaceutical Preparations and Identification of a Novel Degradation Product by LCMS-IT-TOF. Molecules. 2018 Jul 19;23(7). pii: E1771. doi: 10.3390/molecules23071771. PubMed PMID: 30029473. 2: Tsounapi P, Honda M, Dimitriadis F, Koukos S, Hikita K, Zachariou A, Sofikitis N, Takenaka A. Effects of a micronutrient supplementation combined with a phosphodiesterase type 5 inhibitor on sperm quantitative and qualitative parameters, percentage of mature spermatozoa and sperm capacity to undergo hyperactivation: A randomised controlled trial. Andrologia. 2018 Jul 10:e13071. doi: 10.1111/and.13071. [Epub ahead of print] PubMed PMID: 29987899. 3: Huyut Z, Bakan N, Yıldırım S, Alp HH. Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis. Med Sci Monit Basic Res. 2018 Mar 13 [revised 2018 Jan 1];24:47-58. doi: 10.12659/MSMBR.908504. PubMed PMID: 29557941; PubMed Central PMCID: PMC5865409. 4: Kadoh Y, Miyoshi H, Matsumura T, Tanaka Y, Hongu M, Kimura M, Takedomi K, Omori K, Kotera J, Sasaki T, Kobayashi T, Taniguchi H, Watanabe Y, Kojima K, Sakamoto T, Himiyama T, Kawanishi E. Discovery of 2-[(E)-2-(7-Fluoro-3-methylquinoxalin-2-yl)vinyl]-6-pyrrolidin-1-yl-N-(tetrahydro -2H-pyran-4-yl)pyrimidin-4-amine Hydrochloride as a Highly Selective PDE10A Inhibitor. Chem Pharm Bull (Tokyo). 2018;66(3):243-250. doi: 10.1248/cpb.c17-00783. PubMed PMID: 29491258. 5: Corona G, Maggi M, Jannini EA. EDEUS, a Real-Life Study on the Users of Phosphodiesterase Type 5 Inhibitors: Prevalence, Perceptions, and Health Care-Seeking Behavior Among European Men With a Focus on 2nd-Generation Avanafil. Sex Med. 2018 Mar;6(1):15-23. doi: 10.1016/j.esxm.2017.10.003. Epub 2017 Dec 21. PubMed PMID: 29275958; PubMed Central PMCID: PMC5815971. 6: Di Luigi L, Sansone M, Sansone A, Ceci R, Duranti G, Borrione P, Crescioli C, Sgrò P, Sabatini S. Phosphodiesterase Type 5 Inhibitors, Sport and Doping. Curr Sports Med Rep. 2017 Nov/Dec;16(6):443-447. doi: 10.1249/JSR.0000000000000422. Review. PubMed PMID: 29135645. 7: Yafi FA, Sharlip ID, Becher EF. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction. Sex Med Rev. 2018 Apr;6(2):242-252. doi: 10.1016/j.sxmr.2017.08.001. Epub 2017 Oct 12. Review. PubMed PMID: 28923561. 8: Kunimoto R, Bajorath J. Exploring sets of molecules from patents and relationships to other active compounds in chemical space networks. J Comput Aided Mol Des. 2017 Sep;31(9):779-788. doi: 10.1007/s10822-017-0061-2. Epub 2017 Sep 4. PubMed PMID: 28871390. 9: Limoncin E, Gravina GL, Corona G, Maggi M, Ciocca G, Lenzi A, Jannini EA. Erectile function recovery in men treated with phosphodiesterase type 5 inhibitor administration after bilateral nerve-sparing radical prostatectomy: a systematic review of placebo-controlled randomized trials with trial sequential analysis. Andrology. 2017 Sep;5(5):863-872. doi: 10.1111/andr.12403. Epub 2017 Aug 8. Review. PubMed PMID: 28787547. 10: Berges R, Schremmer D, Limberg R. [Avanafil for the treatment of erectile dysfunction in practice. Non-interventional study AVANTI]. MMW Fortschr Med. 2017 Jun;159(Suppl 5):16-21. doi: 10.1007/s15006-017-9804-1. Epub 2017 Jun 22. German. PubMed PMID: 28643292. 11: Park HJ, Kim SW, Kim JJ, Lee SW, Paick JS, Ahn TY, Park K, Park JK, Park NC. A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Therapeutic Confirmatory Study to Evaluate the Safety and Efficacy of Avanafil in Korean Patients with Erectile Dysfunction. J Korean Med Sci. 2017 Jun;32(6):1016-1023. doi: 10.3346/jkms.2017.32.6.1016. PubMed PMID: 28480661; PubMed Central PMCID: PMC5426242. 12: Sperling H. [Side effects of erectile dysfunction drug treatment]. Urologe A. 2017 Apr;56(4):451-455. doi: 10.1007/s00120-017-0341-4. German. PubMed PMID: 28251255. 13: Korkmaz-Icöz S, Radovits T, Szabó G. Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure. Br J Pharmacol. 2018 Jan;175(2):223-231. doi: 10.1111/bph.13749. Epub 2017 Mar 23. Review. PubMed PMID: 28213937; PubMed Central PMCID: PMC5758391. 14: Lorenz C, Lesimple P, Bukowiecki R, Zink A, Inak G, Mlody B, Singh M, Semtner M, Mah N, Auré K, Leong M, Zabiegalov O, Lyras EM, Pfiffer V, Fauler B, Eichhorst J, Wiesner B, Huebner N, Priller J, Mielke T, Meierhofer D, Izsvák Z, Meier JC, Bouillaud F, Adjaye J, Schuelke M, Wanker EE, Lombès A, Prigione A. Human iPSC-Derived Neural Progenitors Are an Effective Drug Discovery Model for Neurological mtDNA Disorders. Cell Stem Cell. 2017 May 4;20(5):659-674.e9. doi: 10.1016/j.stem.2016.12.013. Epub 2017 Jan 26. PubMed PMID: 28132834. 15: Soliman KA, Ibrahim HK, Ghorab MM. Effects of different combinations of nanocrystallization technologies on avanafil nanoparticles: in vitro, in vivo and stability evaluation. Int J Pharm. 2017 Jan 30;517(1-2):148-156. doi: 10.1016/j.ijpharm.2016.12.012. Epub 2016 Dec 7. PubMed PMID: 27939570. 16: Mostafa T. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors. Sex Med Rev. 2016 Jul;4(3):270-284. doi: 10.1016/j.sxmr.2015.12.005. Epub 2016 Mar 19. Review. PubMed PMID: 27871960. 17: Li AS, Pomeranz HD. Food and Drug Administration Adverse Event Reports of Retinal Vascular Occlusions Associated With Phosphodiesterase Type 5 Inhibitor Use. J Neuroophthalmol. 2016 Dec;36(4):480-481. PubMed PMID: 27851718. 18: Soliman KA, Ibrahim HK, Ghorab MM. Formulation of avanafil in a solid self-nanoemulsifying drug delivery system for enhanced oral delivery. Eur J Pharm Sci. 2016 Oct 10;93:447-55. doi: 10.1016/j.ejps.2016.08.050. Epub 2016 Aug 31. PubMed PMID: 27590128. 19: Soliman KA, Ibrahim HK, Ghorab MM. Effect of different polymers on avanafil-β-cyclodextrin inclusion complex: in vitro and in vivo evaluation. Int J Pharm. 2016 Oct 15;512(1):168-177. doi: 10.1016/j.ijpharm.2016.08.044. Epub 2016 Aug 27. PubMed PMID: 27576665. 20: Zurawin JL, Stewart CA, Anaissie JE, Yafi FA, Hellstrom WJ. Avanafil for the treatment of erectile dysfunction. Expert Rev Clin Pharmacol. 2016 Sep;9(9):1163-70. doi: 10.1080/17512433.2016.1212655. Epub 2016 Aug 2. Review. PubMed PMID: 27416913.

View History

LX-1031

LX-1031

Lactosyl isothiocyanate

Lactosyl isothiocyanate

Roquefortine

Roquefortine

OP-1250

OP-1250